S

    SNSE (SNSE)

    Official site

    BIOTECHNOLOGY

    $13.85
    +0.85 (+6.54%)

    Last updated: Jun 15, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(12/22)
    Avg Surprise
    -1097.01%

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$-5.45
    Range$-10.07 - $-0.98
    4 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$-0.67+87.7%
    7d ago$-3.90+28.3%
    Current$-5.45
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Sep 30, 2026
    EPS Consensus$-5.67
    Range$-10.44 - $-1.00
    4 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$-0.72+87.3%
    7d ago$-4.08+28.0%
    Current$-5.67
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-92.57---
    Sep 26EST
    		-$-5.67---
    Jun 26EST
    		-$-5.45---
    Mar 26
    Reported May 15
    		$-131.45$-0.62-21101.61%Miss-48138.5%
    Dec 25
    Reported Mar 30
    		$-3.74$-4.81+22.25%Beat-1271.0%
    Sep 25
    Reported Nov 14
    		$-3.62$-0.23-1473.91%Miss-1148.3%
    Jun 25
    Reported Aug 5
    		$-3.91$-0.24-1529.17%Miss-1296.4%
    Mar 25
    Reported May 6
    		$-0.27$-0.26-4.81%Miss+14.8%
    Dec 24
    Reported Mar 28
    		$-0.27$-0.29+5.93%Beat+9.1%
    Sep 24
    Reported Nov 14
    		$-0.29$-0.31+6.45%Beat-3.6%
    Jun 24
    Reported Aug 6
    		$-0.28$-0.29+3.45%Beat+9.7%
    Mar 24
    Reported May 9
    		$-0.32$-0.28-14.29%Miss+3.0%
    Dec 23
    Reported Feb 28
    		$-0.30$-0.31+3.23%Beat+25.0%
    Sep 23
    Reported Nov 7
    		$-0.28$-0.34+17.65%Beat+36.4%
    Jun 23
    Reported Aug 3
    		$-0.31$-0.33+6.06%Beat+8.8%
    Mar 23
    Reported May 9
    		$-0.33$-0.36+8.33%Beat+17.5%
    Dec 22
    Reported Mar 23
    		$-0.40$-0.40+0.00%Beat-33.3%
    Sep 22
    Reported Nov 8
    		$-0.44$-0.37-18.92%Miss-37.5%
    Jun 22
    Reported Aug 9
    		$-0.34$-0.39+12.82%Beat-6.3%
    Mar 22
    Reported May 10
    		$-0.40$-0.35-14.29%Miss+4.8%
    Dec 21
    Reported Mar 10
    		$-0.30$-0.34+11.76%Beat+88.9%
    Sep 21
    Reported Nov 9
    		$-0.32$-0.24-33.33%Miss+98.5%
    Jun 21
    Reported Aug 4
    		$-0.32$-0.29-10.34%Miss-
    Mar 21
    Reported May 12
    		$-0.42$-0.30-40.00%Miss-
    Dec 20
    Reported Mar 25
    		$-2.71$-2.96+8.45%Beat-
    Sep 19
    Reported Dec 31
    		$-20.81$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.79
    SMA 20$15.96
    SMA 50$23.03
    SMA 200$16.29
    EMA 10$13.96
    EMA 20$16.12
    EMA 50$20.17
    EMA 200$17.77

    MACD

    Line: -2.91Signal: -2.88Hist: -0.03

    ADX

    ADX: 26.2+DI: 18.6-DI: 24.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down92.0
    PSAR$10.78

    Bollinger Bands

    Upper Band$21.62
    Lower Band$10.29
    %B Position7098%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    38.8

    Momentum Oscillators

    Stoch %K16.5
    Stoch %D8.6
    Williams %R-71.4
    ROC (10d)-30.0%
    Momentum-5.94
    CCI (20d)-48.9
    MFI (14d)42.6

    Volatility Measures

    ATR (14d)$2.68(19.3%)
    StdDev (20d)2.83
    Hist Vol163.2%(High)

    Volume Flow

    VWAP$14.71
    OBV142.2M
    AD Line20.3B
    CMF (20d)-0.433

    Volume Metrics

    Avg Vol (20d)56.0K
    Vol Ratio3.9x(High)
    VWMA (20d)$15.48

    Pivot Points

    R3$15.87
    R2$14.49
    R1$13.75
    Pivot Point$12.37
    S1$11.63
    S2$10.25
    S3$9.51

    Advanced Oscillators

    TSI-34.13
    Ultimate Osc30.0
    KST-394.85

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$0$0$-4,851,000$0$0$544,000$0$0$0$2.85M$0$0
    Cost of Revenue$132.96M$4.78M$-4,851,000$37,000$30,000$139,000$140,000$135,000$137,000$135,000$455,000$491,000
    Gross Profit$-132,957,000$67,000N/A$-37,000$-30,000$-139,000$-140,000$-135,000$-137,000$-135,000$-455,000$-491,000
    Operating Expenses$37.67M$4.96M$4.85M$5.21M$7.27M$7.18M$7.68M$7.65M$8.59M$8.01M$7.28M$9.69M
    R&D$17.96M$2.17M$2.54M$2.53M$3.73M$4.49M$4.64M$4.58M$4.92M$4.49M$3.82M$4.48M
    SG&A$19.71M$2.79M$2.31M$2.67M$3.55M$2.83M$3.19M$3.20M$3.81M$3.65M$3.92M$5.39M
    Operating Income$-170,627,000$-4,957,000$-4,851,000$-5,206,000$-7,274,000$-7,323,000$-7,823,000$-7,787,000$-8,730,000$-8,141,999$-7,737,000$-10,185,000
    Interest Income$392,000$223,000$289,000$321,000$405,000$522,000$591,000$669,000$768,000$826,000$877,000$952,000
    Interest Expense$0$3,000$6,000$10,000$13,000$17,000$21,000$24,000$28,000$31,000$33,000$38,000
    Income Before Tax$-170,236,000$-4,717,000$-4,569,000$-4,936,000$-6,864,000$-7,770,000$-7,253,000$-7,142,000$-7,992,000$-7,414,000$-7,124,000$-9,386,000
    Income Tax Expense$0$0$0$0$0$0$0$0$93,724$1.46M$-332,000$106,000
    Net Income$-170,236,000$-4,717,000$-4,569,000$-4,936,000$-6,864,000$-7,770,000$-7,253,000$-7,142,000$-7,992,000$-7,414,000$-7,124,000$-9,386,000
    EBITDA$-170,236,000$-4,680,000$-4,529,000$-4,889,000$-6,817,000$-7,614,000$-7,092,000$-6,983,000$-7,827,000$-7,247,999$-6,636,000$-8,857,000
    EBITN/A$-4,714,000$-4,563,000$-4,926,000$-6,851,000$-7,753,000$-7,232,000$-7,118,000$-7,964,000$-7,382,999$-7,091,000$-9,348,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SNSE

    News

    Sensei Biotherapeutics stock trades steadily as cash runway supports oncology pipeline

    Sensei Biotherapeutics (SNSE) stock is trading steadily, anchored by a cash balance of $61.7 million as of March 31, 2024, which is projected to fund operations into the second half of 2026. This allows the clinical-stage immuno-oncology company to advance its lead program, SNS-101, an antibody targeting VISTA for solid tumors, as well as its broader preclinical pipeline. The company reported a net loss of $7.3 million in Q1 2024, reflecting a decrease in R&D spending to $4.6 million while maintaining stable general and administrative costs, indicating careful financial management in a high-risk sector.

    Ad-hoc-news.de•7/20/26•
    Somewhat-Bullish

    Sensei Biotherapeutics Company Profile & Introduction

    This article provides a company profile and introduction to Sensei Biotherapeutics. It details the company's focus and operations within the biotechnology sector. The content includes key information about its business activities and market position.

    Moomoo•6/26/26•
    Neutral

    Faeth Therapeutics (FTH) CFO adds 17,413 shares via revocable trust purchases

    Faeth Therapeutics (FTH) CFO Brian C. Stephenson, through his revocable trust, purchased a total of 17,413 shares of the company's common stock in open-market transactions on June 22-23, 2026. The purchases were made at weighted average prices ranging from $19.5765 to $26.31 per share across eight separate transactions. After these acquisitions, the trust indirectly holds all 17,413 shares, with Stephenson maintaining sole voting and investment power.

    Stock Titan•6/25/26•
    Neutral

    Suvretta and Cowen report 7.8% holdings in Faeth Therapeutics (FTH)

    Suvretta Capital Management, Aaron Cowen, and Averill Master Fund have disclosed significant passive ownership stakes in Faeth Therapeutics (FTH) through a joint Schedule 13G filing. Suvretta and Cowen reported a beneficial ownership of 7.8% (2,020,103 shares), while Averill Master Fund holds 6.7% (1,722,652 shares), based on 25,778,754 shares outstanding as of June 15, 2026. The filing emphasizes that these holdings represent passive investments by their advisory clients.

    Stock Titan•6/24/26•
    Neutral

    S2G Investments takes 9.99% stake in Faeth Therapeutics (FTH)

    S2G Investments, LLC has reported a 9.99% beneficial ownership stake in Faeth Therapeutics (FTH), totaling 2,575,401 shares of common stock. This stake resulted from the conversion of Series B Non-Voting Convertible Preferred Stock on June 15, 2026. S2G Investments has an elected Beneficial Ownership Limitation of 9.99%, meaning additional convertible preferred shares are not currently counted towards their beneficial ownership.

    Stock Titan•6/23/26•
    Neutral

    Frequently Asked Questions About SNSE

    Does SNSE pay dividends?
    SNSE (SNSE) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In